PurposeTo investigate factors associated with good response to intravitreal bevacizumab (IVB) in central serous chorioretinopathy (CSC) patients.MethodsWe retrospectively reviewed 42 eyes of CSC patients of symptom duration more than 3 months who received a single or multiple successive IVBs on an as-needed basis (0.05 ml, 1.25 mg). High responders (HRs) were defined as complete resolution of subretinal fluid (SRF) on spectral domain optical coherence tomography (SD-OCT). Moderate responders (MRs) were defined as SRF resolution of 50-99% of pretreatment volume and poor responders (PRs) as SRF resolution <50%. Clinical, SD-OCT, fluorescein, and indocyanine green angiography findings were analyzed to find factors associated with HR. Descriptive statistics for all demographic and clinical variables were calculated, and comparisons were made using Wilcoxon's matched-pairs signed-rank test, the Mann-Whitney U-test for means with continuous data, Pearson's χ 2 test, and Fisher's exact test for categorical data.ResultsThe mean number of IVB was 1.9. At postoperative 1 month, there were 10 (24%) HRs, 18 (43%) MRs, and 14 (33%) PRs. At the last follow-up (the mean 8.6 months), there were 25 HRs (60%), 9 MRs (21%), and 8 PRs (19%). Thicker subfoveal choroid (P=0.036), smaller lesion diameter (P=0.019), and better baseline best-corrected visual acuity (P=0.002) predicted HRs at postoperative 1 month. HR at the last follow-up was associated with classic pattern fluorescein angiography finding.ConclusionsSuboptimal effects of IVB on persistent CSC suggest primary IVB on selective cases with better vision, smaller lesion, and thicker choroid at baseline.
Bibliographical noteFunding Information:
Andrew Lotery has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Allergan, Inc.; Bayer HealthCare Pharmaceuticals; Q Chip; Roche; Novartis Pharmaceuticals Corporation. Served as a speaker or a member of a speakers bureau for: Bayer HealthCare Pharmaceuticals Novartis Pharmaceuticals Corporation. Received grants for clinical research from: Novartis Pharmaceuticals Corporation Gyu Ah Kim, MD, has disclosed no relevant financial relationships. Tyler Hyungtaek Rim, MD, has disclosed no relevant financial relationships. Sung Chul Lee, MD, has disclosed no relevant financial relationships. Suk Ho Byeon, MD, has disclosed no relevant financial relationships. Hyoung Jun Koh, MD, has disclosed the following relevant financial relationships. Sung Soo Kim, MD, has disclosed no relevant financial relationships. Christopher Seungkyu Lee, MD, has disclosed no relevant financial relationships.
All Science Journal Classification (ASJC) codes
- Sensory Systems